Medical Weight Loss with Expert Care from The Belgravia Centre

Clinically proven weight loss treatments can help people lose a significant proportion of their body weight — and at The Belgravia Centre, we combine them with specialist monitoring, lifestyle guidance and ongoing care.

The results can be substantial. In major clinical trials, people taking Mounjaro lost an average of up to around 22% of their starting weight over 72 weeks, while those taking Wegovy lost around 15% over 68 weeks, alongside diet and lifestyle changes.

At Belgravia, the medicine is only one part of your programme. We assess your health and suitability, help determine the appropriate treatment and dose, monitor your progress and support the changes that can help you lose weight safely and improve your health.

CLICK HERE TO SUBMIT OUR WEIGHT LOSS FORM

Your treatment options

Depending on your health, preferences and clinical suitability, your programme may include one of several licensed weight management medicines.

Mounjaro

Mounjaro (tirzepatide) is a once-weekly injection that acts on two hormones involved in appetite and blood sugar regulation: GIP and GLP-1.

It can reduce hunger, help you feel fuller for longer and make it easier to eat smaller portions. In a major 72-week study, average weight loss ranged from around 16% to 22.5%, depending on dose. GOV.UK

Wegovy

Wegovy (semaglutide) works by mimicking GLP-1, a naturally occurring hormone involved in appetite regulation.

It helps reduce hunger and increase feelings of fullness. In a major clinical trial of the once-weekly injection, participants lost an average of approximately 15% of their starting body weight over 68 weeks. New England Journal of Medicine

Wegovy tablets

Wegovy is also available as a once-daily tablet, providing an alternative for suitable patients who would prefer not to use injections.

In a clinical trial, the 25mg tablet produced an average weight reduction of approximately 14% over 64 weeks, alongside lifestyle intervention. PubMed

Foundayo tablets

Foundayo (orforglipron) is a newly licensed once-daily GLP-1 tablet. Unlike Wegovy tablets, it can be taken at any time of day without food or water restrictions.

At the highest licensed dose, clinical trial data showed an average reduction of around 12% of starting body weight over 72 weeks. GOV.UK

Which treatment is appropriate for you will depend on your health, starting weight, medical history, preferences and individual response.

CLICK HERE TO START YOUR WEIGHT LOSS JOURNEY

The Belgravia way

Weight loss treatment shouldn't simply mean receiving medication.

Your Belgravia programme is clinically managed from the beginning, with your progress, treatment and dose reviewed as you lose weight. We'll also guide you on nutrition, protein intake, exercise, hydration, sleep and maintaining muscle mass, helping your health improve alongside your weight.

Our aim is not simply to help you lose as much weight as possible. It is to help you achieve effective, sustainable weight loss while protecting and improving your overall health.

See your progress

The scales show how much weight you've lost. Regular photographs can show you the difference.

With our comprehensive programme, you can visit the clinic every month for consistent progress photographs, allowing you and our team to visually track how your body is changing.

We'll also review your progress and treatment at each visit, including whether your dose remains appropriate.

Choose the level of support you need

Flexible Weight Management allows you to manage most of your programme from home, with ongoing support and an in-clinic review every six months to assess your progress and continued suitability.

Comprehensive Weight Management provides closer face-to-face support, with the option to visit us every month for progress photographs and a review of your weight, treatment and dose.

Both programmes include professional health and lifestyle guidance throughout.

Side effects and safety

These medicines are effective, but like all medicines they can cause side effects.

The most common are gastrointestinal and can include nausea, diarrhoea, constipation, indigestion, bloating and vomiting. They are often more noticeable when treatment begins or the dose increases and may improve as your body adjusts. Gastrointestinal effects were also the most frequently reported adverse events in the major semaglutide, tirzepatide and orforglipron trials. New England Journal of Medicine

We'll explain what to expect, increase doses appropriately and review any problems you experience. You should always read the Patient Information Leaflet supplied with your medicine and seek medical advice for severe, persistent or concerning symptoms.

These treatments are not suitable for everyone, which is why clinical assessment and continued monitoring matter.

Supporting better health as you lose weight

Weight loss is only part of the objective.

During your programme we'll help you focus on the things that can make your weight loss healthier and easier to maintain, including adequate protein, balanced nutrition, hydration, fibre, regular movement and resistance exercise.

Preserving muscle is particularly important during significant weight loss, so we'll encourage appropriate protein intake and strength-based activity rather than focusing solely on the number on the scales.

Start with a free consultation

Complete our Weight Management Form and we'll review the information you provide and we will normally contact you straight away, although it may take up to 24 hours during the week.

If treatment may be suitable, we'll arrange a free consultation at The Belgravia Centre with a specialist weight management pharmacist to discuss your health, goals and the treatment options that may be appropriate for you.

CLICK HERE TO COMPLETE OUR WEIGHT LOSS ENQUIRY FORM

All treatment is subject to clinical assessment and individual suitability. Weight loss varies between individuals. Clinical trial figures are averages and do not guarantee individual results.